The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | A study showing that treatment is not always necessary for duodenal-type follicular lymphoma
Celso Arrais, MD, PhD, Federal University of São Paulo, São Paulo, Brazil, discusses a retrospective study investigating outcomes of Brazilian patients with duodenal-type follicular lymphoma. The study highlights that most patients were asymptomatic and could be effectively monitored without immediate treatment, with some experiencing spontaneous complete remission. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
